Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic

다국어 초록 (Multilingual Abstract)

The coronavirus disease 2019 (COVID-19) pandemic rapidly spread globally. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, is a positive-sense single-stranded RNA virus with a reported fatality rate ranging from 1% to 7%, and people with immune-compromised conditions, children, and older adults are particularly vulnerable. Respiratory failure and cytokine storm-induced multiple organ failure are the major causes of death. This article highlights the innate and adaptive immune mechanisms of host cells activated in response to SARS-CoV-2 infection and possible therapeutic approaches against COVID-19. Some potential drugs proven to be effective for other viral diseases are under clinical trials now for use against COVID-19. Examples include inhibitors of RNA-dependent RNA polymerase (remdesivir, favipiravir, ribavirin), viral protein synthesis (ivermectin, lopinavir/ritonavir), and fusion of the viral membrane with host cells (chloroquine, hydroxychloroquine, nitazoxanide, and umifenovir). This article also presents the intellectual groundwork for the ongoing development of vaccines in preclinical and clinical trials, explaining potential candidates (live attenuated-whole virus vaccines, inactivated vaccines, subunit vaccines, DNA-based vaccines, protein-based vaccines, nanoparticle-based vaccines, virus-like particles and mRNA-based vaccines). Designing and developing an effective vaccine (both prophylactic and therapeutic) would be a long-term solution and the most effective way to eliminate the COVID-19 pandemic.

참고문헌 (Reference)

1 Pardi N, "mRNA vaccines : a new era in vaccinology" 17 : 261-279, 2018

2 Rosales-Mendoza S, "Will plant-made biopharmaceuticals play a role in the fight against COVID-19?" 20 : 545-548, 2020

3 Roldao A, "Virus-like particles in vaccine development" 9 : 1149-1176, 2010

4 Chackerian B, "Virus-like particles : flexible platforms for vaccine development" 6 : 381-390, 2007

5 Kandeel M, "Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease" 251 : 117627-, 2020

6 He Y, "Vaccine design for severe acute respiratory syndrome coronavirus" 18 : 327-332, 2005

7 Parr JB, "Time to reassess tocilizumab's role in COVID-19 pneumonia" 181 : 12-15, 2021

8 Al-Hajeri H, "Therapeutic role of immunomodulators during the COVID-19 pandemic : a narrative review" 134 : 160-179, 2022

9 Warren TK, "Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys" 531 : 381-385, 2016

10 Negru PA, "Therapeutic dilemmas in addressing SARS-CoV-2 infection : Favipiravir versus Remdesivir" 147 : 112700-, 2022

11 Zhong J, "The immunology of COVID-19 : is immune modulation an option for treatment?" 2 : e428-e436, 2020

12 Casadevall A, "The convalescent sera option for containing COVID-19" 130 : 1545-1548, 2020

13 Chen WH, "The SARS-CoV-2 vaccine pipeline : an overview" 7 : 61-64, 2020

14 Livingston EH, "The Johnson & Johnson vaccine for COVID-19" 325 : 1575-, 2021

15 Jasenosky LD, "The FDA-approved oral drug nitazoxanide amplifies host antiviral responses and inhibits Ebola virus" 19 : 1279-1290, 2019

16 Caly L, "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro" 178 : 104787-, 2020

17 Liu WJ, "T-cell immunity of SARS-CoV : implications for vaccine development against MERS-CoV" 137 : 82-92, 2017

18 Alhazzani W, "Surviving Sepsis Campaign : guidelines on the management of critically ill adults with coronavirus disease 2019(COVID-19)" 46 : 854-887, 2020

19 Kadam RU, "Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol" 114 : 206-214, 2017

20 Lim B, "Stability of the osmoregulated promoter-derived proP mRNA is posttranscriptionally regulated by RNase III in Escherichia coli" 197 : 1297-1305, 2015

21 Nicolas P, "Safety of oral ivermectin during pregnancy : a systematic review and meta-analysis" 8 : e92-e100, 2020

22 Navarro M, "Safety of high-dose ivermectin : a systematic review and meta-analysis" 75 : 827-834, 2020

23 Mammen MP, "Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure"

24 Gupte V, "Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients : a retrospective analysis of active surveillance database" 22 : 1-, 2022

25 Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor" 181 : 271-280, 2020

26 Chen Y, "SARS-CoV-2 : virus dynamics and host response" 20 : 515-516, 2020

27 Jiang S, "Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome" 11 : 1405-1413, 2012

28 Lane JC, "Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis : a multinational, retrospective study" 2 : E698-E711, 2020

29 Arabi YM, "Ribavirin and interferon therapy for critically Ill patients with Middle East respiratory syndrome : a multicenter observational study" 70 : 1837-1844, 2020

30 Al-Tawfiq JA, "Remdesivir as a possible therapeutic option for the COVID-19" 34 : 101615-, 2020

31 Wang M, "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro" 30 : 269-271, 2020

32 Sharma A, "Recent developments for Pseudomonas vaccines" 7 : 999-1011, 2011

33 Li Z, "Rapid review for the anti-coronavirus effect of remdesivir" 14 : 73-76, 2020

34 AlQahtani M, "Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease" 12 : 4925-, 2022

35 Zhang J, "Progress and prospects on vaccine development against SARS-CoV-2" 8 : 153-, 2020

36 Sanders JM, "Pharmacologic treatments for coronavirus disease 2019(COVID-19) : a review" 323 : 1824-1836, 2020

37 Zhou G, "Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2" 16 : 1718-1723, 2020

38 Channappanavar R, "Pathogenic human coronavirus infections : causes and consequences of cytokine storm and immunopathology" 39 : 529-539, 2017

39 Foolad F, "Oral versus aerosolized ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplant recipients" 68 : 1641-1649, 2019

40 Pardi N, "Nucleoside modified mRNA vaccines for infectious diseases" 1499 : 109-121, 2017

41 Khalili JS, "Novel coronavirus treatment with ribavirin : groundwork for an evaluation concerning COVID-19" 92 : 740-746, 2020

42 Rossignol JF, "Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus" 9 : 227-230, 2016

43 Rossignol JF, "Nitazoxanide : a first-in-class broad-spectrum antiviral agent" 110 : 94-103, 2014

44 De Clercq E, "New nucleoside analogues for the treatment of hemorrhagic fever virus infections" 14 : 3962-3968, 2019

45 Schneider CS, "Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation" 3 : e1601556-, 2017

46 Al-Halifa S, "Nanoparticle-based vaccines against respiratory viruses" 10 : 22-, 2019

47 Laval JM, "Nanobiotechnology and its role in the development of new analytical devices" 125 : 29-33, 2000

48 Knights AJ, "Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients" 58 : 325-338, 2009

49 Baran I., "Medical sciences and biotechnology book" Izmir Kavram Vocational School 65-78, 2020

50 Frieman M, "Mechanisms of severe acute respiratory syndrome pathogenesis and innate immunomodulation" 72 : 672-685, 2008

51 Graci JD, "Mechanisms of action of ribavirin against distinct viruses" 16 : 37-48, 2006

52 Cvetkovic RS, "Lopinavir/ritonavir : a review of its use in the management of HIV infection" 63 : 769-802, 2003

53 Ketkar H, "Lack of efficacy of ivermectin for prevention of a lethal Zika virus infection in a murine system" 95 : 38-40, 2019

54 Svarovskaia ES, "L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions" 213 : 1240-1247, 2015

55 Phua J, "Intensive care management of coronavirus disease 2019(COVID-19) : challenges and recommendations" 8 : 506-517, 2020

56 Hu TY, "Insights from nanomedicine into chloroquine efficacy against COVID-19" 15 : 247-249, 2020

57 Ohto T, "Inhibition of the inflammatory pathway enhances both the in vitro and in vivo transfection activity of exogenous in vitro-transcribed mRNAs delivered by lipid nanoparticles" 42 : 299-302, 2019

58 Bhimraj A, "Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19" 2020

59 Yao X, "In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)" 71 : 732-739, 2020

60 Zarghampoor F, "Improved translation efficiency of therapeutic mRNA" 707 : 231-238, 2019

61 Lu X, "Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice" 122 : 496-502, 2007

62 Gautret P, "Hydroxychloroquine and azithromycin as a treatment of COVID-19 : results of an open-label non-randomized clinical trial" 56 : 105949-, 2020

63 Liang Y, "Highlight of immune pathogenic response and hematopathologic effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 infection" 11 : 1022-, 2020

64 Altınbas S, "Hepatitis C virus infection in pregnancy : an update" 43 : 12-21, 2020

65 Khadke S, "Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19 : a review of the phases of illness and therapeutic agents" 17 : 154-, 2020

66 Furuta Y, "Favipiravir (T-705), a novel viral RNA polymerase inhibitor" 100 : 446-454, 2013

67 Furuta Y, "Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase" 93 : 449-463, 2017

68 Chen N, "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study" 395 : 507-513, 2020

69 Chen Y, "Emerging coronaviruses: genome structure, replication, and pathogenesis" 92 : 418-423, 2020

70 Zheng HY, "Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients" 17 : 541-543, 2020

71 Mortola E, "Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system" 576 : 174-178, 2004

72 Bosaeed M, "Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial" 28 : 602-608, 2022

73 Udwadia ZF, "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial" 103 : 62-71, 2021

74 Savarino A, "Effects of chloroquine on viral infections : an old drug against today's diseases?" 3 : 722-727, 2003

75 Xu X, "Effective treatment of severe COVID-19 patients with tocilizumab" 117 : 10970-10975, 2020

76 Hermine O, "Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia : a randomized clinical trial" 181 : 32-40, 2021

77 Lu H, "Drug treatment options for the 2019-new coronavirus(2019-nCoV)" 14 : 69-71, 2020

78 Siegel D, "Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-Nucleoside (GS-5734) for the treatment of ebola and emerging viruses" 60 : 1648-1661, 2017

79 RECOVERY Collaborative Group, "Dexamethasone in hospitalized patients with Covid-19" 384 : 693-704, 2021

80 Bloch EM, "Deployment of convalescent plasma for the prevention and treatment of COVID-19" 130 : 2757-2765, 2020

81 Zhang J, "Current status of potential therapeutic candidates for the COVID-19 crisis" 87 : 59-73, 2020

82 Ji W, "Cross-species transmission of the newly identified coronavirus 2019-nCoV" 92 : 433-440, 2020

83 Fauci AS, "Covid-19 : navigating the uncharted" 382 : 1268-1269, 2020

84 Agostini ML, "Coronavirus susceptibility to the antiviral remdesivir(GS-5734)is mediated by the viral polymerase and the proofreading exoribonuclease" 9 : e00221-e00318, 2018

85 Sumirtanurdin R, "Coronavirus disease 2019 vaccine development : an overview" 34 : 134-144, 2021

86 McCreary EK, "Coronavirus disease 2019 treatment: a review of early and emerging options" 7 : ofaa105-, 2020

87 Roback JD, "Convalescent plasma to treat COVID-19 : possibilities and challenges" 323 : 1561-1562, 2020

88 Jahanafrooz Z, "Comparison of DNA and mRNA vaccines against cancer" 25 : 552-560, 2020

89 Sheahan TP, "Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV" 11 : 222-, 2020

90 Ruan Q, "Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China" 46 : 846-848, 2020

91 Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China" 395 : 497-506, 2020

92 Wang Z, "Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment" 14 : 64-68, 2020

93 Vincent MJ, "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread" 2 : 69-, 2005

94 Colson P, "Chloroquine and hydroxychloroquine as available weapons to fight COVID-19" 2020

95 Tai W, "Characterization of the receptor-binding domain(RBD)of 2019 novel coronavirus : implication for development of RBD protein as a viral attachment inhibitor and vaccine" 17 : 613-620, 2020

96 Ou X, "Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV" 11 : 1620-, 2020

97 Onder G, "Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy" 323 : 1775-1776, 2020

98 Lim J, "Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR" 35 : e79-, 2020

99 Ndwandwe D, "COVID-19 vaccines" 71 : 111-116, 2021

100 Amawi H, "COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics" 11 : 245-248, 2020

101 Gattinoni L, "COVID-19 does not lead to a"Typical"acute respiratory distress syndrome" 201 : 1299-1300, 2020

102 Loo KY, "COVID-19 : insights into potential vaccines" 9 : 605-, 2021

103 Sheahan TP, "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses" 9 : eaal3653-, 2017

104 Gao J, "Breakthrough : chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies" 14 : 72-73, 2020

105 Zimmer C, "Bad news wrapped in protein: inside the coronavirus genome"

106 Takashima Y, "Artificial molecular clamp : a novel device for synthetic polymerases" 50 : 7524-7528, 2011

107 Simsek Yavuz S, "Antiviral treatment of COVID-19" 50 (50): 611-619, 2020

108 Khamitov RA, "Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures" 53 : 9-13, 2008

109 Wu R, "An update on current therapeutic drugs treating COVID-19" 6 : 56-70, 2020

110 Li Y, "An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)"

111 Peng XL, "Advances in the design and development of SARS-CoV-2 vaccines" 8 : 67-, 2021

112 Higdon MM, "A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease"

113 Cao J, "A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs" 114 : 1-10, 2015

114 Tu YF, "A review of SARS-CoV-2 and the ongoing clinical trials" 21 : 2657-, 2020

115 Zhou P, "A pneumonia outbreak associated with a new coronavirus of probable bat origin" 579 : 270-273, 2020

116 Jiang S, "A novel coronavirus(2019-nCoV)causing pneumonia-associated respiratory syndrome" 17 : 554-, 2020

117 Zhu N, "A novel coronavirus from patients with pneumonia in China, 2019" 382 : 727-733, 2020

118 Rahman MM, "A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges" 1-22, 2022